263 related articles for article (PubMed ID: 23039366)
1. Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study.
Ngian GS; Stevens W; Prior D; Gabbay E; Roddy J; Tran A; Minson R; Hill C; Chow K; Sahhar J; Proudman S; Nikpour M
Arthritis Res Ther; 2012 Oct; 14(5):R213. PubMed ID: 23039366
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: A cohort study in China.
Zhao J; Wang Q; Liu Y; Tian Z; Guo X; Wang H; Lai J; Huang C; Yang X; Li M; Zeng X
Int J Cardiol; 2017 Jun; 236():432-437. PubMed ID: 28159359
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors of pulmonary hypertension associated with connective tissue disease: pulmonary artery size measured by chest CT.
Li X; Zhang C; Sun X; Yang X; Zhang M; Wang Q; Zhu Y
Rheumatology (Oxford); 2020 Nov; 59(11):3221-3228. PubMed ID: 32221604
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and Survival of Anti-U1 RNP Antibody-Positive Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.
Sobanski V; Giovannelli J; Lynch BM; Schreiber BE; Nihtyanova SI; Harvey J; Handler CE; Denton CP; Coghlan JG
Arthritis Rheumatol; 2016 Feb; 68(2):484-93. PubMed ID: 26415038
[TBL] [Abstract][Full Text] [Related]
5. Mortality and prognostic factors in connective tissue disease-associated pulmonary arterial hypertension patients complicated with right heart failure.
Deng X; Jiang N; Huang C; Zhou S; Peng L; Zhang L; Liu J; Wang L; Zhou J; Wang Q; Weng L; Peng J; Zhao J; Li M; Zeng X
Int J Rheum Dis; 2023 May; 26(5):862-869. PubMed ID: 36892249
[TBL] [Abstract][Full Text] [Related]
6. Survival and prognostic factors in patients with connective tissue disease-associated pulmonary hypertension diagnosed by echocardiography: results from a Korean nationwide registry.
Kang KY; Jeon CH; Choi SJ; Yoon BY; Choi CB; Lee CH; Suh CH; Lee CW; Cho CS; Nam EJ; Koh EM; Kim HY; Choi HJ; Kim HA; Jun JB; Lee J; Kim J; Ji JD; Min JK; Kim KJ; Shin K; So MW; Kwon SR; Kim SK; Nah SS; Kwok SK; Lee SK; Lee SW; Park SH; Park W; Park YB; Lee YH; Lee SS; Yoo DH
Int J Rheum Dis; 2017 Sep; 20(9):1227-1236. PubMed ID: 26214170
[TBL] [Abstract][Full Text] [Related]
7. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era.
Condliffe R; Kiely DG; Peacock AJ; Corris PA; Gibbs JS; Vrapi F; Das C; Elliot CA; Johnson M; DeSoyza J; Torpy C; Goldsmith K; Hodgkins D; Hughes RJ; Pepke-Zaba J; Coghlan JG
Am J Respir Crit Care Med; 2009 Jan; 179(2):151-7. PubMed ID: 18931333
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors in pulmonary arterial hypertension with Dana Point group 1.
Adachi S; Hirashiki A; Nakano Y; Shimazu S; Murohara T; Kondo T
Life Sci; 2014 Nov; 118(2):404-9. PubMed ID: 24632476
[TBL] [Abstract][Full Text] [Related]
9. Right atrial function for the prediction of prognosis in connective tissue disease-associated pulmonary arterial hypertension: a study with two-dimensional speckle tracking.
Bai Y; Yang J; Liu J; Ning H; Zhang R
Int J Cardiovasc Imaging; 2019 Sep; 35(9):1637-1649. PubMed ID: 31037473
[TBL] [Abstract][Full Text] [Related]
10. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).
Benza RL; Miller DP; Gomberg-Maitland M; Frantz RP; Foreman AJ; Coffey CS; Frost A; Barst RJ; Badesch DB; Elliott CG; Liou TG; McGoon MD
Circulation; 2010 Jul; 122(2):164-72. PubMed ID: 20585012
[TBL] [Abstract][Full Text] [Related]
11. Undiagnosed connective tissue diseases: High prevalence in pulmonary arterial hypertension patients.
Cavagna L; Codullo V; Ghio S; Scirè CA; Guzzafame E; Scelsi L; Rossi S; Montecucco C; Caporali R
Medicine (Baltimore); 2016 Sep; 95(39):e4827. PubMed ID: 27684814
[TBL] [Abstract][Full Text] [Related]
12. Comparison of baseline characteristics and survival between patients with idiopathic and connective tissue disease-related pulmonary arterial hypertension.
Ruiz-Cano MJ; Escribano P; Alonso R; Delgado J; Carreira P; Velazquez T; Sanchez MA; Sáenz de la Calzada C
J Heart Lung Transplant; 2009 Jun; 28(6):621-7. PubMed ID: 19481024
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Outcomes in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta-Analyses of Randomized, Controlled Trials and Observational Registries.
Khanna D; Zhao C; Saggar R; Mathai SC; Chung L; Coghlan JG; Shah M; Hartney J; McLaughlin V
Arthritis Rheumatol; 2021 May; 73(5):837-847. PubMed ID: 33538058
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: a single-centre cohort.
Shirai Y; Yasuoka H; Okano Y; Takeuchi T; Satoh T; Kuwana M
Rheumatology (Oxford); 2012 Oct; 51(10):1846-54. PubMed ID: 22740623
[TBL] [Abstract][Full Text] [Related]
15. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry.
Chung L; Farber HW; Benza R; Miller DP; Parsons L; Hassoun PM; McGoon M; Nicolls MR; Zamanian RT
Chest; 2014 Dec; 146(6):1494-1504. PubMed ID: 24992469
[TBL] [Abstract][Full Text] [Related]
16. Predictors of Long-term Outcomes in Patients With Connective Tissue Disease Associated With Pulmonary Arterial Hypertension.
Nakayama K; Nakajima Y; Tanaka R; Hirata KI; Emoto N
J Clin Rheumatol; 2021 Dec; 27(8):e371-e377. PubMed ID: 32511146
[TBL] [Abstract][Full Text] [Related]
17. [Risk factors for death and the clinical features of different subtypes of patients with pulmonary arterial hypertension related to congenital heart disease].
Xu ZY; Li QQ; Zhang C; Zhang HS; Gu H
Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):315-322. PubMed ID: 32370483
[No Abstract] [Full Text] [Related]
18. Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis.
Kuwana M; Blair C; Takahashi T; Langley J; Coghlan JG
Ann Rheum Dis; 2020 May; 79(5):626-634. PubMed ID: 32161055
[TBL] [Abstract][Full Text] [Related]
19. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial.
Fischer A; Denton CP; Matucci-Cerinic M; Gillies H; Blair C; Tislow J; Nathan SD
Respir Med; 2016 Aug; 117():254-63. PubMed ID: 27492539
[TBL] [Abstract][Full Text] [Related]
20. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
Denton CP; Humbert M; Rubin L; Black CM
Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
